Annexin Pharmaceuticals AB (publ) (STO:ANNX)

STO:ANNX Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	9.59	8.01	12.29	10.7	10.98
Research & Development	40.81	36.03	28.37	42.13	33.64
Operating Expenses	50.4	44.04	40.66	52.83	44.62
Operating Income	-50.4	-44.04	-40.66	-52.83	-44.62
Interest Expense	-	-	-0	-1.86	-0.5
Interest & Investment Income	0.23	0.12	-	-	-
Earnings From Equity Investments	-	-	-	0.95	-
Currency Exchange Gain (Loss)	-0.08	-0.14	-0.07	1.59	0.89
Other Non Operating Income (Expenses)	-0	-	-	-	-
Pretax Income	-50.25	-44.05	-40.73	-52.14	-44.24
Net Income	-50.25	-44.05	-40.73	-52.14	-44.24
Net Income to Common	-50.25	-44.05	-40.73	-52.14	-44.24
Shares Outstanding (Basic)	452	167	146	82	62
Shares Outstanding (Diluted)	452	167	146	82	62
Shares Change (YoY)	170.59%	14.23%	78.30%	33.40%	247.79%
EPS (Basic)	-0.11	-0.26	-0.28	-0.64	-0.72
EPS (Diluted)	-0.11	-0.26	-0.28	-0.64	-0.72
Free Cash Flow	-50.23	-43.4	-41.17	-45.02	-39.2
Free Cash Flow Per Share	-0.11	-0.26	-0.28	-0.55	-0.64
EBITDA	-50.2	-43.85	-40.46	-52.63	-44.43
D&A For EBITDA	0.19	0.19	0.19	0.19	0.19
EBIT	-50.4	-44.04	-40.66	-52.83	-44.62

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.